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6/j.bSeroconversion rates following influenza vaccination in patients with hematologic malignancies after hema-
topoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of
our diagnostic study was to determine the rate of seroconversion after 1 or 2 doses of a novel split virion,
inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients
(ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first
dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by hemaggluti-
nation inhibition assay. Seroconversion was defined by either an AB titer of#1:10 before and$1:40 after or
$1:10 before and$4-fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3
autologous HSCT) received 1 dose and 11 of these patients 2 doses of the vaccine. The rate of seroconver-
sion was 41.2% (95% confidence interval [CI] 18.4-67.1) after the first and 81.8% (95% CI 48.2-97.7) after the
second dose. Patients who failed to seroconvert after 1 dose of the vaccine were more likely to receive any
immunosuppressive agent (P 5 .003), but time elapsed after or type of HSCT, age, sex, or chronic graft-
versus-host disease was not different when compared to patients with seroconversion. In patients with he-
matologic malignancies after HSCT the rate of seroconversion after a first dose of an adjuvanted H1N1
influenza A vaccine was poor, but increased after a second dose.
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A novel split virion, inactivated, adjuvanted pan-
demic H1N1 influenza A vaccine (A/California/7/
2009 NYMC X-179A; Pandemrix) was licensed in
most European countries in 2009. The Centers for
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bmt.2011.02.004fluenza A vaccination for adult individuals, especially
for immunocompromised or patients with chronic
medical conditions. Patients with hematologic malig-
nancies after hematopoietic stem cell transplantation
(HSCT) seem to be at a higher risk of seasonal and
H1N1 influenza A–related complications with a re-
ported case fatality of up to 25% for seasonal [2-7]
and up to 33% for H1N1 influenza A [8-11].
Protection against influenza is primarily mediated by
virus-specific antibodies (AB) and depends on the hu-
moral immune response [12,13], which is impaired
in these individuals. Based on data from seasonal
influenza, it is assumed that a H1N1 virus-specific an-
tibody titer of $1:40 is associated with an approxi-
mately 50% lower risk of developing H1N1
influenza A and is therefore referred to as a seroprotec-
tive titer [14]. The immunogenicity of seasonal influ-
enza vaccines in patients after HSCT seems lower
compared to the general population, especially when
vaccinated \6 months after HSCT (reviewed in [7]
and [15]). First reports are also indicating weak re-
sponse rates to vaccination against the 2009 H1N1 in-
fluenza A [16].
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sults in a higher rate of seroconversion is still under de-
bate. Thus, the aim of the present study was to
investigate the rate of seroconversion after 1 and 2
doses of a novel H1N1 influenza A vaccine (Clinical-
Trials.gov Identifier: NCT01017172).METHODS
Patients
Adult patients with hematologic malignancies after
HSCT from the Medical Department of the Johann
Wolfgang Goethe University, who were routinely
scheduled to receive a H1N1 influenza A vaccine,
were asked to participate in this diagnostic study.
The study protocol was approved by the local ethics
committee and complied with the ICH-GCP guide-
line on the conduct of clinical trials and the Declara-
tion of Helsinki. All patients gave written informed
consent.
A 10-mL blood sample was taken immediately be-
fore (day 0) and 3 weeks after the first dose of the vac-
cine (day 21). On day 21, a second dose of the vaccine
was given, and subsequently, a third blood sample was
taken 21 days after the second vaccination on day 42.
All blood samples were centrifuged (10 minutes at
1500 r.p.m.), and the sera were frozen (220C) for fur-
ther analysis. Clinical data were retrieved from the
medical records.
Vaccine
Split influenza virus, inactivated, containing 3.75-
mg antigen equivalent to A/California/7/2009 (H1N1)
v-like strain (X-179A) hemagglutinin with AS03 adju-
vant composed of squalene (10.69 mg), DL-a-tocoph-
erol (11.86 mg), and polysorbate 80 (4.86 mg)
(Pandemrix, GlaxoSmithKline Biologicals, Dresden,
Germany) was used for an intramuscular vaccination
into the deltoid muscle of the nondominant arm. The
second dose was given into the opposite arm.
Hemagglutination Inhibition Test
Hemagglutination inhibition assay (HAI) was done
after removing naturally occurring, nonspecific inhibi-
tors from the sera, according to the World Health
Organization guidance on influenza diagnosis and sur-
veillance and as previously described [17,18]. Reagents
used for testing were standardized fresh red blood cells
(RBC) of turkeys in Alsever’s solution (Bundesinstitut
f€urRisikobewertung,Alt-Marienfelde,Berlin,Germany)
and H1N1-Virus split antigen (A/California/7/2009
NYMC X-179A; Pandemrix; GlaxoSmithKline Bio-
logicals). Titers below the detection limit of 1:10
were assigned a value of 1:5 for the purpose of calculat-
ing the geometric mean titer. In accordance with theEuropean and international guidance, seroconversion
after vaccination was defined by either an AB titer of
#1:10 before and $1:40 after or $1:10 before and
$4-fold increase in AB titer 21 days after vaccination
[14,17], respectively.
Statistical Analysis
To compare antibody titers, the geometric mean
with the corresponding 95% confidence interval (CI)
was calculated. Other values are shown as mean values
6 standard deviation if not indicated otherwise. Con-
tinuous variables were compared using the Wilcoxon
matched pairs test, nominal values were compared us-
ing Fisher’s exact test. All tests were 2-tailed for a sig-
nificance level of .05. Statistical analyses were done
using SPSS for Windows, release 16 (SPSS Inc.,
Chicago, IL).RESULTS
The study was started on November 11, 2009, and
the last blood sample was taken on February 1, 2010.
Seventeen patients (5 females) were included in the
study and received 1 dose of the AS03-adjuvanted
H1N1 influenza vaccine. All 17 patients were offered
a second dose of the vaccine 21 days after the first
dose. Eleven of these 17 patients received a second
dose 3 weeks after the first dose and had serum samples
taken on days 0, 21, and 42 available for analysis. The
other 6 patients decided against a second dose, because
local and federal health authorities publicized a single
dose. None of the patients refused the second dose
because of adverse events.
Before vaccination (day 0), 3 of 17 patients (17.6%)
had a seroprotective HAI titer of 1:40 or more. Three
weeks (day 21) after the first dose of the H1N1 influ-
enza A vaccine, 9 of 17 patients (52.9%) and 3 weeks
after the second dose (day 42), 10 of 11 patients
(90.9%) had a seroprotective HAI titer of 1:40 or
more. Seroconversion was detected in 41.2% (7 of 17
patients) at day 21 after the first and in 81.8% (9 of
11 patients) at day 42 following the second dose of
the H1N1 influenza A vaccine (Table 1). When focus-
ing on the subgroup of 11 patients who received 2
doses, 6 patients failed to seroconvert after the first
dose, but 4 of these 6 seroconverted after the second
dose. Accordingly, the geometric mean HAI titer in-
creased significantly after the second dose when com-
pared to the HAI titer developed after the first dose
(P 5 .002).
The geometricmeanHAI titer for patients with se-
roconversion after 1 dose was 182 (95% CI, 119-280)
compared to 13.8 (95% CI, 5.2-36.9) for those who
failed to seroconvert (P 5 .003).
The mean time between vaccination and HSCT
was 19.7 (range: 4.7-49.3) months. Two patients
Table 1. Rates of Seroconversion and Seroprotection Before, After 1 and 2 Intramuscular Doses of the Novel adjuvanted H1N1
influenza vaccine (A/California/7/2009) in Patients after HSCT
Day 0
(Before Vaccination)
Day 21
(After First Dose)
Day 42
(After Second Dose)
Geometric mean HAI titer—value (95% CI) n 5 17 7.7 (4.6-13.0) 40 (16.8-95.2) na
n 5 11 9.7 (4.3-22) 59.6 (20.2-175) 381 (121-1195)
Seroprotection rate—% (95% CI) n 5 17 17.6 (3.8-43.4) 52.9 (27.8-77) na
n 5 11 27.3 (6.0-61.0) 63.6 (30.8-89.1) 90.9 (58.7-99.8)
Seroconversion rate—% (95% CI) n 5 17 na 41.2 (18.4-67.1) na
n 5 11 na 45.5 (16.8-76.6) 81.8 (48.2-97.7)
n indicates number of patients; HAI, hemagglutination inhibition test; 95% CI, 95% confidence interval; na, not applicable; HSCT, hematopoietic stem cell
transplantation.
All 17 included patients were offered a second dose, which was administered to 11 of the 17 patients. Results of all patients (n5 17) and of those with
a second dose (n5 11) are shown separately. Seroprotection was defined as an AB titer of$1:40. Seroconversion was defined as an AB titer of#1:10
before and $1:40 after or $1:10 before and $4-fold increase in AB titer after vaccination.
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whereupon 1 did seroconvert and 1 did not. The latter
seroconverted after the second dose, which was admin-
istered 6.7 months after HSCT. Six patients had
myeloablative and 11 patients reduced-intensity
conditioning (RIC) before allogeneic (n5 14) and au-
tologous HSCT (n 5 3). Chronic graft-versus-host
disease (cGVHD) was present in 7 of the 14 patients
following allogeneic HSCT. None of the patients
had acute GVHD (aGVHD) at the time of vaccina-
tion. Three patients experienced new onsets or wors-
ening of the cGVHD after vaccination. Apart from
that, the vaccine was well tolerated and no other severe
clinical adverse events were found in our study.
Patients who received immunosuppressive therapy
at the time of vaccination to treat or prevent GVHD
after allogeneic HSCT were far more likely not to se-
roconvert after 1 dose of the vaccine (P5 .003). Single
or combined immunosuppressive therapy consisted of
calcineurin inhibitors (n 5 6), corticosteroids (n 5 3),
mycophenolate mofetil (n 5 2), everolimus (n 5 1),
and rituximab within 6 months before vaccination
(n5 1). However, the only 2 patients who failed to se-
roconvert after 2 doses of the vaccine were both\60
years old and not receiving any immunosuppressive
therapy. One of them was female and received alloge-
neic HSCT after RIC 49.3 months before vaccina-
tion. The other patient was male and was vaccinated
25.7 months following autologous HSCT after mye-
loablative conditioning. In contrast to the latter
described patient, the other 2 autologously trans-
planted patients seroconverted after the first dose of
the vaccine, and AB titers hugely increased after the
second dose.
No significant difference was found between the 2
groups when comparing for age, sex, type of HSCT,
time elapsed after HSCT, or H1N1 prevaccination
titer. Neither the CD4 cell count nor the immuno-
globulin G levels differed between the 2 groups.
Table 2 summarizes the major clinical and laboratory
characteristics of the enrolled patients.DISCUSSION
In our study, the rate of patients with seroprotec-
tion (HAI titer of $1:40) increased from 17.6% to
52.9% after the first and to 90.9% after the second
dose of the adjuvanted H1N1 vaccine. Likewise, the
rate of seroconversion increased from 41.2% after
the first to 81.8% after the second dose of the vaccine.
The European guidance for the evaluation of influ-
enza vaccines suggests a seroconversion rate of more
than 40% as well as a seroprotection rate of more
than 70% after influenza vaccination of 18- to 60-
year-old adults in order to be judged as efficacious
[19]. After application of 1 dose, the seroconversion
rate was only marginally above the recommended
rate and the seroprotection rate was lower. After 2
doses, the recommended cutoffs were well exceeded.
Up to now, there has been only 1 published study,
by Issa et al. [16], who measured the AB titer in 82
HSCT patients at variable time points after a single
dose of a nonadjuvanted H1N1 2009 influenza A vac-
cine and found a seroprotection rate of 51%, which is
well in agreement with our smaller study using an adju-
vantedH1N12009 influenzaAvaccine. Seroconversion
rates could not be specified, because prevaccination ti-
ters were not assessed in this study. In the study by
Issa et al. [16], immunosuppressive therapy was not as-
sociated with response to vaccination, whereas in our
study, thiswas theonly significant difference comparing
patientswho seroconverted after 1 dose of the vaccine to
those who did not. Interestingly, the only 2 patients not
responding after the second dose of the vaccine were
both not receiving immunosuppressive therapy.
Comparing our results to earlier studies investigat-
ing the efficacy of seasonal influenza vaccines inHSCT
recipients has several limitations. The most important
limitation is the small size of our study. Moreover, the
so-far published studies are very heterogeneous and in-
clude patients with a variety of hematologic malignan-
cies who have received different interventions and
treatments at different time points relative to the
Table 2. Demografic and Disease-Related Characteristics of the Participants Comparing Those Who Seroconverted After the
First Dose to Those Who Did Not
Seroconverter NonSeroconverter P Value
n (%) 7 (41.2) 10 (58.8)
Age (years)—mean (±SD) 46.7 (±19.4) 44.4 (±11.4) .8
Male sex—n (%) 5 (71.4) 7 (70) 1.0
Time since HSCT (months)—mean (±SD) 15.4 (±6.7) 22.7 (±17.7) .7
Myeloablative chemotherapy before HSCT—n (%) 4 (57) 2 (20) .2
Allogeneic HSCT—n (%) 5 (71.4) 9 (90) .5
Chronic GVHD at the time of vaccination—n (%) 3 of 5 following allogeneic HSCT (60%) 4 of 9 following allogeneic HSCT (44%) 1.0
Any immunosuppressive therapy—n (%) 0 of 5 following allogeneic HSCT (0%) 8 of 9 following allogeneic HSCT (89%) .003
Geometric mean HAI titer before the
vaccination (day 0)—value (95% CI)
6.3 (3.6-11) 8.8 (3.6-21.4) .5
Geometric mean HAI titer after the
first dose (day 21)—value (95% CI)
182 (119-280) 13.8 (5.2-36.9) .003
CD4+ cells (/mL)—mean (± SD) 250.7 (±127.1) 349.9 (±423.9) .6
Immunoglobulin G (mg/dL)— mean (±SD) 768.0 (±341.5) 713.9 (±353.4) .8
N indicates number of patients with antibody titers measured before and 21 days after vaccination; SD, standard deviation; HSCT, hematopoietic stem
cell transplantation; 95% CI, 95% confidence interval; P values are given for the comparison of seroconverter and nonseroconverter; HAI, hemagglu-
tination inhibition test; GVHD, graft-versus-host disease.
Most values are given as means 6 standard deviation unless otherwise stated.
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cially monoclonal antibodies such as rituximab, can
lower the ability to respond to a novel antigen, but
may not limit responses to recall antigens [20]. More-
over, seasonal influenza strains can circulate over sev-
eral years, and many patients are found to have high
AB titers before vaccination, which is known to affect
seroconversion rates [21]. Thus, the calendar year in
which the influenza vaccination study was performed
also needs to be taken into account. The 2009 H1N1
influenza A is a new variant with limited AB crossreac-
tivity to earlier seasonal H1N1 influenza A strains.
Therefore, investigating these new vaccines could offer
new insights in a patient population with low rates of
protective prevaccination immunity [22].
In accordance with the variety of influenza vaccina-
tion studies in HSCT recipients, the rate of seroconver-
sion after 1 dose wasmuch lower in our study compared
to studies in healthy adults reporting rates of.95% [23].
Whether a second dose of an influenza vaccine can en-
hance immune response in patients at risk for not re-
sponding has been the subject of several studies. In
healthy elderly individuals (.61 years), 3 studies (2
with seasonal and 1 with a novel H1N1 2009 vaccine)
showed that a second dose of these nonadjuvanted influ-
enza vaccines enhances rates of seroprotection and sero-
conversion [24-26]. Two studies in younger individuals
(\12 years), 1 using a nonadjuvanted and 11 an
adjuvanted H1N1 influenza A vaccine, showed
increased seroprotection rates after a second dose
[27,28]. A previous report from our group showed
a significantly increased rate of seroconversion in HIV-
1 infected patients after 2 doses of the novel adjuvanted
H1N1 vaccine [29]. In patients with malignancies, 2
smaller, nonrandomized studies found an increased se-
roconversion rate [30,31], but a third nonrandomized
study in HSCT recipients [32], as well as 1 small, ran-domized trial, failed to show a difference after 2 doses
of a nonadjuvanted seasonal influenza vaccine [33].
In our study, a second dose of the adjuvantedH1N1
vaccine resulted in a significant increase of protectiveAB
titers. Most studies in HSCT patients, including ours,
are small and lack randomization; thus, clear answers
to the question of the time point of vaccination and the
clinical benefit of a second dose do not exist. But this is-
sue needs to be addressed. Seasonal influenza, as well as
2009H1N1influenzaA, is a relevant threat toHSCTre-
cipients, with a reported case fatality ranging up to 33%.
The 2009 H1N1 vaccine was overall well tolerated
in our small cohort. Both, Issa et al. [16] (n5 82) using
a nonadjuvanted, and Ditschkowski et al. [11] (n5 55)
using an adjuvanted vaccine, described the H1N1 vac-
cine as well tolerated and safe.
In summary, our results suggest that 1 dose of the
split virion, inactivated, adjuvanted pandemic H1N1
influenza A vaccine resulted in a low rate of protection
in patients with hematologic malignancies after
HSCT. A second dose seems to enhance protection
and should be systematically studied.ACKNOWLEDGMENTS
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